74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Novo Nordisk A-S (Class B)
Closed
622.4 5.12
Overview
Share price change
24h
Min
608.7
Max
622.9
Income | 929M 28B |
|---|---|
Sales | 14B 86B |
P/E Sector Avg | 26.38 73.394 |
EPS | 6.34 |
Dividend yield | 2.64 |
Profit margin | 32.947 |
Employees | 76,302 |
EBITDA | 4.1B 39B |
Recommendations | Buy |
|---|---|
12 Months Forecast | +9.53 upside |
Dividend yield Sector Avg | 2.64% 3.09% |
|---|---|
Next Earnings | 7 May 2025 |
Market Cap | 490B 2.6T |
|---|---|
Previous open | 617.28 |
Previous close | 622.4 |
Novo Nordisk A-S (Class B) Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Novo Nordisk A-S (Class B) Forecast
Price Target
By TipRanks
9.53% upside
12 Months Forecast
Average 1,162.73 DKK 9.53%
High 1,550 DKK
Low 720 DKK
Based on 11 Wall Street analysts offering 12 month price targets forNovo Nordisk A-S (Class B) - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Novo Nordisk A-S (Class B)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
